BioPharmSignal logoBioPharmSignal

Biotech News

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Achieve Life Sciences (ACHV)Achieve Life SciencesCompany update

ACHV (ACHV) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is achv.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ACHVAchieve Life Sciences2026-03-26 12:30 EST

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

ACHVAchieve Life Sciences2026-06-22 12:30 EST

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

SLSSELLAS Life Sciences Group, Inc.2025-11-03 14:00 EST

SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

SLSSELLAS Life Sciences Group, Inc.2026-05-12 20:05 EST

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

TECHBio-Techne2026-05-04 11:00 EST

Bio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference

AZTAAzenta Life Sciences2026-04-07 12:15 EST

Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

TECHBio-Techne2025-12-23 12:00 EST

Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference

View all latest news

Achieve Life Sciences

Achieve Life Sciences is a specialty company focused on smoking-cessation and nicotine dependence. Its story is centered on a focused public-health treatment niche rather than broad biotech breadth.

Recent company news

ACHVAchieve Life Sciences2026-06-29 12:30 EST

Achieve Life Sciences Joins Russell 2000® Index

ACHVAchieve Life Sciences2026-06-22 12:30 EST

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

ACHVAchieve Life Sciences2026-06-02 12:30 EST

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

ACHVAchieve Life Sciences2026-05-19 18:15 EST

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

ACHVAchieve Life Sciences2026-05-12 11:05 EST

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

Stock data

Close
6.18 USD
Market cap
516.38M USD
Exchange
NASDAQ
Sector
Life Science Tools
Location
United States